Cyclophosphamide: 142 Real Stories

142 stories match cyclophosphamide. 141 of them mention chemotherapy.

Cancer Stories

A patient, who was diagnosed with Breast CancerBreast Cancer

Breast Cancer Treatment During Pregnancy

Patient Info: Anonymized, Female, Under 40

She completed chemotherapy during pregnancy and delivered a healthy daughter at 36 weeks. Radiotherapy remained ahead at the latest follow-up.

PubMed Central
OutcomeCare Ongoing
SI
Breast Cancer

Stage II HER2-Positive Breast Cancer With Anti-Yo Paraneoplastic Cerebellar Degeneration

Patient Info: Anonymized, female, 50s | Stage II

Biomarkers: HER2 positive

Her severe anti-Yo paraneoplastic cerebellar syndrome did not meaningfully respond to IVIG or cancer treatment. She became wheelchair-dependent and ultimately required long-term care, with only moderate improvement in ataxia after rehabilitation.

PubMed Central
OutcomeNot reported
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Breast cancer recurrence involving the bladder and bones

Patient Info: Anonymized, Female | Stage IV

Biomarkers: Initial breast cancer: ER-positive, PR-positive, HER2-negative. Bladder metastasis: ER-positive, PR-negative, HER2 1+.

Metastatic Site: bladder, bone, rectosigmoid region, anorectal region

She died in October 2016 from pulmonary haemorrhage, 47 months after metastatic disease was diagnosed.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Invasive Lobular CarcinomaBreast Cancer

Breast cancer spreading to the colon, rectum and peritoneal surfaces

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: Primary tumor: ER >80% positive; PR 50–60% positive; HER2 negative; E-cadherin positive. Later colorectal metastases: ER positive; PR negative; HER2 negative; CK7 positive; CK20 negative; CDX2 negative.

Metastatic Site: colon, rectum, peritoneum, diaphragm, liver, bowel,…

Metastatic breast cancer was subsequently confirmed in the colon and rectum, with later laparoscopic biopsies showing peritoneal and additional intra-abdominal metastatic disease.

PubMed Central
OutcomeSetback / Progression
A patient, who was diagnosed with Stage II Breast CancerBreast Cancer

Stage II metaplastic breast cancer in a 47-year-old man

Patient Info: Anonymized, Male, 40s | Stage II

Biomarkers: ER 1%; PR negative; HER2 negative; E-cadherin positive; p63 positive; genetic testing reported no abnormal mutations

Two years after surgery he was doing well, with only occasional pain at the mastectomy site and a negative recent mammogram of the left breast.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage III Breast CancerBreast Cancer

Triple receptor-positive neuroendocrine breast cancer in a 32-year-old woman

Patient Info: Anonymized, Female, Under 40 | Stage III

Biomarkers: ER positive; PR positive; HER2 positive; neuron-specific enolase positive; synaptophysin positive

She was stable on follow-up and was receiving adjuvant chest-wall radiation plus systemic chemotherapy and trastuzumab-based therapy.

PubMed Central
OutcomeCare Ongoing
SI
Ovarian Cancer

Stage IV Ovarian Cancer With 20 Years of Tumor-Free Survival

Patient Info: Anonymized, female, 50s | Stage IV

Biomarkers: BRCA1 negative, BRCA2 negative

Metastatic Site: peritoneum, liver, right adrenal gland

Regular follow-up found no recurrence or other tumor, and at 20 years of follow-up she remained tumor-free with good health and quality of life.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Invasive Lobular CarcinomaBreast Cancer

Breast cancer returning 21 years later as a solitary parotid metastasis

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: Parotid metastasis ER positive; PR positive; HER2 borderline by IHC but FISH 1.82

Metastatic Site: left parotid gland

More than 5 months after the parotid metastasis was diagnosed, the tumour had slightly decreased in size and her metastatic disease remained stable on endocrine therapy.

PubMed Central
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Breast cancer returning years later in the biceps muscle

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: ER positive

Metastatic Site: left biceps muscle

Her arm symptoms improved considerably after radiotherapy, and MRI 6 months later showed a significant decrease in the size of the biceps tumour.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Breast CancerBreast Cancer

Male Breast Cancer Treatment Complicated by Stevens-Johnson Syndrome

Patient Info: Anonymized, male, 60s

After the third chemotherapy cycle he developed severe Stevens-Johnson syndrome with disseminated intravascular coagulation and multiorgan failure, and he died after care was shifted to comfort measures.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Breast CancerBreast Cancer

Mixed epithelial and mesenchymal metaplastic breast carcinoma: no recurrence 1 year after surgery and adjuvant therapy

Patient Info: Anonymized, Female, 40s

Biomarkers: Mixed metaplastic breast cancer: epithelial part ER/PR/HER2-positive; mesenchymal part ER/PR-negative with weak HER2. Ki-67 ~20%.

As of March 2014, she was doing well with no recurrence or metastasis 1 year after modified radical mastectomy, adjuvant CEF/Taxotere chemotherapy, and tamoxifen.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Inflammatory Breast CancerBreast Cancer

Breast invasive ductal carcinoma with coexisting inflammatory myofibroblastic tumor: disease-free after mastectomy, TAC, and tamoxifen

Patient Info: Anonymized, Female, Under 40

Biomarkers: Breast cancer: ER/PR-positive with HER2 2+ and p53-positive. Separate inflammatory myofibroblastic tumor had ALK/vimentin/actin/S-100 markers.

As of August 2013, she remained disease-free 2 years after modified radical mastectomy, 6 courses of TAC chemotherapy, and tamoxifen.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Invasive Ductal CarcinomaBreast Cancer

BRCA1-associated right invasive ductal carcinoma followed by left acinic cell carcinoma of the breast

Patient Info: Anonymized, Female, 40s

Biomarkers: Constitutional BRCA1 mutation. Right breast cancer was ER/PR positive, HER2 negative; later left tumor was triple-negative with TP53 change.

After treatment for right invasive ductal carcinoma and later contralateral acinic cell carcinoma, she was alive and well 19 months after the acinic cell carcinoma surgery, with no evidence of disease while continuing hormonal therapy.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Invasive Ductal CarcinomaBreast Cancer

Recurrent HER2-amplified breast cancer: complete remission on trastuzumab-based therapy

Patient Info: Anonymized, Female, 40s | Stage Metastatic/Advanced

Biomarkers: Primary tumor was ER/PR negative and HER2 not amplified. Recurrent lymph-node disease became ER/PR positive and HER2 amplified by FISH.

Metastatic Site: left axillary and infraclavicular lymph nodes

After HER2-amplified nodal recurrence, paclitaxel plus trastuzumab produced complete clinical remission; she continued trastuzumab monotherapy with tolerable neuropathy.

PubMed Central
OutcomeResponding Well